Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders

7 Apr 2022

Abstract excerpt

Abstract Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response is highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the amount of variance in symptom severity among clozapine-treated patients explained by PRSs (R2) and examined the association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bipolar Disorder and Treatment
Share to Genetic Associations and Epidemiology
Share to Schizophrenia research and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35393395
DOI: 10.1038/s41398-022-01884-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disordersPMID 35393395Read ↗

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorderSemantic proximity Read ↗

Medication and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophreniaSemantic proximity Read ↗

Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With SchizophreniaSemantic proximity Read ↗

Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode PsychosisSemantic proximity Read ↗

Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four healthcare systemsSemantic proximity Read ↗

Genomic stratification of clozapine prescription patterns using schizophrenia polygenic scoresSemantic proximity Read ↗

Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessmentSemantic proximity Read ↗

Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19Semantic proximity Read ↗

Multi-Trait Genetic Insights Into Schizophrenia Across Ancestries: Genome-Wide Association Meta-Analyses, Machine Learning, and Drug Repurposing Study.Semantic proximity Read ↗

A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics.Semantic proximity Read ↗

Pharmacogenomic scores in psychiatry: Systematic review of existing evidenceSemantic proximity Read ↗

Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.